About this Journal Submit a Manuscript Table of Contents
Advances in Virology
Volume 2012 (2012), Article ID 548657, 13 pages
http://dx.doi.org/10.1155/2012/548657
Research Article

In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors

1LBPA, CNRS, LabEx LERMIT, Ecole Normale Supérieure de Cachan, 61 Avenue du Président Wilson, 94235 Cachan, France
2School of Life Science, East China Normal University, Shanghai 200062, China
3Laboratoire de Virologie, AP-HP, Hôpital Pitié-Salpêtrière, EA 2387, UPMC Université Paris VI, 75013 Paris, France

Received 3 January 2012; Revised 16 April 2012; Accepted 30 April 2012

Academic Editor: Domenico Genovese

Copyright © 2012 Xiaoju Ni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. O. Brown, “Integration of retroviral DNA,” Current Topics in Microbiology and Immunology, vol. 157, pp. 19–48, 1990. View at Scopus
  2. S. Y. Rhee, T. F. Liu, M. Kiuchi et al., “Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors,” Retrovirology, vol. 5, article 74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Hemelaar, E. Gouws, P. D. Ghys, and S. Osmanov, “Global trends in molecular epidemiology of HIV-1 during 2000–2007,” AIDS, vol. 25, no. 5, pp. 679–689, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Fischetti, O. Opare-Sem, D. Candotti, F. Sarkodie, H. Lee, and J. P. Allain, “Molecular epidemiology of HIV in Ghana: dominance of CRF02_AG,” Journal of Medical Virology, vol. 73, no. 2, pp. 158–166, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Fischetti, O. Opare-Sem, D. Candotti, H. Lee, and J. P. Allain, “Higher viral load may explain the dominance of CRF02_AG in the molecular epidemiology of HIV in Ghana,” AIDS, vol. 18, no. 8, pp. 1208–1210, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. H. F. Njai, Y. Gali, G. Vanham et al., “The predominance of Human Immunodeficiency Virus type I (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness,” Retrovirology, vol. 3, article 40, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. L. F. A. MacHado, M. O. G. Ishak, A. C. R. Vallinoto et al., “Molecular epidemiology of HIV type 1 in Northern Brazil: identification of subtypes C and D and the introduction of CRF02-AG in the amazon region of Brazil,” AIDS Research and Human Retroviruses, vol. 25, no. 10, pp. 961–966, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. J. R. Ye, S. Q. Yu, H. Y. Lu, W. S. Wang, R. L. Xin, and Y. Zeng, “Genetic diversity of HIV type 1 isolated from newly diagnosed subjects (2006-2007) in Beijing, China,” AIDS Research and Human Retroviruses, vol. 28, no. 1, pp. 119–123, 2012.
  9. D. Descamps, M. L. Chaix, B. Montes et al., “Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 12, Article ID dkq380, pp. 2620–2627, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. L. Martínez-Cajas, N. Pant-Pai, M. B. Klein, and M. A. Wainberg, “Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence,” AIDS Reviews, vol. 10, no. 4, pp. 212–223, 2008. View at Scopus
  11. B. S. Taylor, M. E. Sobieszczyk, F. E. McCutchan, and S. M. Hammer, “Medical progress: the challenge of HIV-1 subtype diversity,” New England Journal of Medicine, vol. 358, no. 15, pp. 1590–1602, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Bar-Magen, R. D. Sloan, V. H. Faltenbacher et al., “Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes,” Retrovirology, vol. 6, article 103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Low, N. Prada, M. Topper et al., “Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 10, pp. 4275–4282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Malet, C. Soulie, L. Tchertanov et al., “Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases,” Journal of Medical Virology, vol. 80, no. 5, pp. 754–761, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Fenollar-Ferrer, V. Carnevale, S. Raugei, and P. Carloni, “HIV-1 integrase-DNA interactions investigated by molecular modelling,” Computational and Mathematical Methods in Medicine, vol. 9, no. 3-4, pp. 231–243, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. I. Maïga, I. Malet, C. Soulie et al., “Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes,” Antiviral Therapy, vol. 14, no. 1, pp. 123–129, 2009. View at Scopus
  17. E. Asante-Appiah and A. M. Skalka, “A metal-induced conformational change and activation of HIV-1 integrase,” Journal of Biological Chemistry, vol. 272, no. 26, pp. 16196–16205, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. J. F. Mouscadet, O. Delelis, A. G. Marcelin, and L. Tchertanov, “Resistance to HIV-1 integrase inhibitors: a structural perspective,” Drug Resistance Updates, vol. 13, no. 4-5, pp. 139–150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Hare, A. M. Vos, R. F. Clayton, J. W. Thuring, M. D. Cummings, and P. Cherepanov, “Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 46, pp. 20057–20062, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Hare, S. S. Gupta, E. Valkov, A. Engelman, and P. Cherepanov, “Retroviral intasome assembly and inhibition of DNA strand transfer,” Nature, vol. 464, no. 7286, pp. 232–236, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. Z. Yin and R. Craigie, “Modeling the HIV-1 intasome: a prototype view of the target of integrase inhibitors,” Viruses, vol. 2, no. 12, pp. 2777–2781, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Guiot, K. Carayon, O. Delelis et al., “Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity,” Journal of Biological Chemistry, vol. 281, no. 32, pp. 22707–22719, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. O. Delelis, I. Malet, L. Na et al., “The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation,” Nucleic Acids Research, vol. 37, no. 4, pp. 1193–1201, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Maurin, F. Bailly, E. Buisine et al., “Spectroscopic studies of diketoacids-metal interactions. A probing tool for the pharmacophoric intermetallic distance in the HIV-1 integrase active site,” Journal of Medicinal Chemistry, vol. 47, no. 22, pp. 5583–5586, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. A. S. Espeseth, P. Felock, A. Wolfe et al., “HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 21, pp. 11244–11249, 2000. View at Scopus
  26. T. Kawasuji, T. Yoshinaga, A. Sato, M. Yodo, T. Fujiwara, and R. Kiyama, “A platform for designing HIV integrase inhibitors. Part 1: 2-Hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores,” Bioorganic and Medicinal Chemistry, vol. 14, no. 24, pp. 8430–8445, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Z. Loizidou, I. Kousiappa, C. D. Zeinalipour-Yazdi, D. A. M. C. Van De Vijver, and L. G. Kostrikis, “Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses,” Biochemistry, vol. 48, no. 1, pp. 4–6, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Hewer, T. Traut, J. Coates, and B. Williams, “Predicted modes of resistance and hypersensensivity confered by natural polymorphisms of HIV-1 integrase,” Antiviral Research, vol. 82, no. 2, article A24, 2009.
  29. A. Ali, R. M. Bandaranayake, Y. Cai et al., “Molecular basis for drug resistance in HIV-1 protease,” Viruses, vol. 2, no. 11, pp. 2509–2535, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. R. M. Bandaranayake, M. Kolli, N. M. King et al., “The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways,” Journal of Virology, vol. 84, no. 19, pp. 9995–10003, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Eswar, B. John, N. Mirkovic et al., “Tools for comparative protein structure modeling and analysis,” Nucleic Acids Research, vol. 31, no. 13, pp. 3375–3380, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. A. Larkin, G. Blackshields, N. P. Brown et al., “Clustal W and Clustal X version 2.0,” Bioinformatics, vol. 23, no. 21, pp. 2947–2948, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. D. Thompson, D. G. Higgins, and T. J. Gibson, “CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice,” Nucleic Acids Research, vol. 22, no. 22, pp. 4673–4680, 1994. View at Scopus
  34. R. A. Friesner, J. L. Banks, R. B. Murphy et al., “Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy,” Journal of Medicinal Chemistry, vol. 47, no. 7, pp. 1739–1749, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. G. M. Morris, H. Ruth, W. Lindstrom et al., “Software news and updates AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility,” Journal of Computational Chemistry, vol. 30, no. 16, pp. 2785–2791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. The PyMOL Molecular Grapics System, 2002.
  37. J. Y. Wang, H. Ling, W. Yang, and R. Craigie, “Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein,” EMBO Journal, vol. 20, no. 24, pp. 7333–7343, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. J. C. H. Chen, J. Krucinski, L. J. W. Miercke et al., “Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 15, pp. 8233–8238, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Y. Shen and A. Sali, “Statistical potential for assessment and prediction of protein structures,” Protein Science, vol. 15, no. 11, pp. 2507–2524, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. J. F. Mouscadet, R. Arora, J. André et al., “HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations,” Journal of Molecular Recognition, vol. 22, no. 6, pp. 480–494, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Maignan, J. P. Guilloteau, Q. Zhou-Liu, C. Clément-Mella, and V. Mikol, “Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases,” Journal of Molecular Biology, vol. 282, no. 2, pp. 359–368, 1998. View at Publisher · View at Google Scholar · View at Scopus
  42. B. R. Brooks, C. L. Brooks, A. D. Mackerell et al., “CHARMM: the biomolecular simulation program,” Journal of Computational Chemistry, vol. 30, no. 10, pp. 1545–1614, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Sali and T. L. Blundell, “Comparative protein modelling by satisfaction of spatial restraints,” Journal of Molecular Biology, vol. 234, no. 3, pp. 779–815, 1993. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Hare, F. Di Nunzio, A. Labeja, J. Wang, A. Engelman, and P. Cherepanov, “Structural basis for functional tetramerization of lentiviral integrase,” PLoS Pathogens, vol. 5, no. 7, Article ID e1000515, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Du, L. Shen, Z. Yu et al., “Hyrtiosal, from the marine sponge Hyrtios erectus, inhibits HIV-1 integrase binding to viral DNA by a new inhibitor binding site,” ChemMedChem, vol. 3, no. 1, pp. 173–180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Lu, H. Z. Ghory, and A. Engelman, “Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase,” Journal of Virology, vol. 79, no. 16, pp. 10356–10368, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. R. A. Laskowski, M. W. Macarthur, D. S. Moss, and J. M. Thornton, “Procheck—a program to check the stereochemical quality of protein structures,” Journal of Applied Crystallography, vol. 26, pp. 283–291, 1993.
  48. S. M. Kerwin, “ChemBioOffice Ultra 2010 suite,” Journal of the American Chemical Society, vol. 132, no. 7, pp. 2466–2467, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. Gaussian 03, Gaussian, Wallingford, UK, 2003.
  50. H. Leh, P. Brodin, J. Bischerour et al., “Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase,” Biochemistry, vol. 39, no. 31, pp. 9285–9294, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. I. Malet, O. Delelis, M. A. Valantin et al., “Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 4, pp. 1351–1358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Agapkina, M. Smolov, S. Barbe et al., “Probing of HIV-1 integrase/DNA interactions using novel analogs of viral DNA,” Journal of Biological Chemistry, vol. 281, no. 17, pp. 11530–11540, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Smolov, M. Gottikh, V. Tashlitskii et al., “Kinetic study of the HIV-1 DNA 3′-end processing: single-turnover property of integrase,” FEBS Journal, vol. 273, no. 6, pp. 1137–1151, 2006. View at Publisher · View at Google Scholar · View at Scopus